Claims for Patent: 9,915,659

Summary for Patent: 9,915,659

Title:	Systems and methods for prognosticating brain tumors
Abstract:	The present invention describes methods of prognosticating patient survival based on an analysis of the ZEB1 gene or gene product. The present invention also describes methods of selecting and/or selecting various therapies based on the analysis of ZEB1, IDH1, PTEN, MGMT and/or RET. Further describes are systems for analyzing ZEB1, IDH1, PTEN, MGMT and/or RET as well as selecting and/or selecting the therapies.
Inventor(s):	Yu; John S. (Los Angeles, CA), Edwards; Lincoln A. (Los Angeles, CA)
Assignee:	CEDARS-SINAI MEDICAL CENTER (Los Angeles, CA)
Application Number:	15/186,188
Patent Claims:	1. A method of treating a brain tumor in a subject, wherein a zinc-finger E-box binding homeobox 1 (ZEB1) dysregulation has been determined to be present in a tumor cell of the brain tumor, comprising: providing an angiogenesis inhibitor; and administering a therapeutically effective amount of the angiogenesis inhibitor to the subject, thereby treating the brain tumor in the subject, wherein said brain tumor is selected from glioblastoma or glioma, and wherein said angiogenesis inhibitor is bevacizumab. 2. The method of claim 1, wherein an absence of an isocitrate dehydrogenase I (IDH1) dysregulation has also been determined in the brain tumor cell. 3. The method of claim 1, further comprising not administering a chemotherapeutic agent to the subject, or stop administering the chemotherapeutic agent to the subject. 4. The method of claim 3, wherein the chemotherapeutic agent is procarbazine, lomustine, and vincristine (PCV). 5. The method of claim 1, wherein the brain tumor is a glioblastoma. 6. The method of claim 1, wherein the brain tumor is a glioma.

Details for Patent 9,915,659

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2033-12-18